BOULDER, Colo., June 12, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today their collaboration with Citogen, the Longwood Group’s customer services and support unit, to establish the company’s first authorized site in Spain. As part of the agreement, Citogen will offer the 7,000-plex SomaScan^® Assay and provide SomaScan data to their customers in Southern Europe supporting biological research across an array of disciplines including clinical research, population health studies and nutrigenomics.

For more than twenty years, SomaLogic has grown from its roots in the research lab to become a global leader in proteomics with technology that delivers the quality and quantity of biological insights life science researchers need - from lab to last mile.

"Our goal is to give research centers throughout Europe access to state-of-the-art technologies available in the market,” said Longwood Group Chief Executive Officer Miguel Giralt. “By offering the SomaScan Platform in our portfolio of services, we complete the vision of providing translational research tools that our clients demand. The ability of the SomaScan technology to measure thousands of proteins in a single sample is a powerful tool for advancing our understanding of the biology of complex diseases.”

Located in Zaragoza, Spain, Citogen offers specialized multiomic services in spatial transcriptomics, proteomics, personalized molecular diagnostics and accredited forensic genetics assays using NGS technology, under the requirements of ENAC (UNE-EN ISO/IEC 17025). The laboratory has more than 20 years of research laboratory experience, specializing in clinical, forensic and reproductive genetics.

“Spain’s established network of research centers, universities and its growing number of biotech companies create great potential for expansion of our proteomics platform, which offers these researchers reliable throughput, reproducibility, high sensitivity and dynamic range,” said SomaLogic Chief Executive Officer Adam Taich. “The Citogen laboratory has the ability to expand the reach of the SomaScan Platform in Europe and we are pleased to be working with this extraordinary research organization to provide their life sciences customers the technology and innovation that will propel their scientific endeavors forward.”

Citogen joins Group 42 Healthcare in the Middle East, Biostar in China, Molecular Genomics in Singapore and FonesLife in Japan as SomaLogic authorized sites around the world. SomaLogic also has authorized sites throughout the United States.

About SomaLogic 
SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow @somalogic on LinkedIn.

Forward Looking Statements 
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Media Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com

Investor Contacts
Marissa Bych
Gilmartin Group LLC
investors@somalogic.com